After discovering uncommon blood clotting in many clients identified with COVID-19, doctors think there may be a link to the density of their blood, known as hyperviscosity, with swelling and clotting.
"IT HAS BEEN A MYSTERY WHY SO MANY PATIENTS WITH COVID-19 HAVE HAD ATYPICAL BLOOD CLOTS."
"It has been a mystery why so many clients with COVID-19 have had atypical blood clots. We recognized we had to think past our typical testing strategies to understand why this may be happening," says lead writer Cheryl Maier, an aide teacher of coagulation and transfusion medication in the pathology and lab medication division at the Emory College Institution of Medication, as well as clinical supervisor of the Unique Coagulation Lab.
"Blood needs to flow efficiently for proper circulation throughout the body. Imagine the distinction in between something streaming such as molasses or honey, rather than such as sprinkle."
The communication, which links hyperviscosity and seriousness of disease, shows up in The Lancet.
The scientists evaluated plasma thickness (density of blood plasma) in 15 seriously sick COVID-19 clients with pneumonia that were confessed to Emory Health care critical care unit (ICUs). All them had plasma thickness degrees over the normal range. The sickest clients had the highest plasma thickness degrees, greater than double normal degrees, and were also more most likely to have a embolism.
Many anti-clot medications are commonly called blood thinners, yet they work by obstructing factors associated with the clotting process and not by actually production the blood much less thick or slim.
"Despite prescribing medications to prevent blood clots to COVID-19 clients, clotting still occurred, which is quite uncommon," says Maier. "One point that stood apart was the incredibly high degrees of fibrinogen, a big sticky healthy protein that increases with swelling and is a key building obstruct for production blood clots."
Maier recognized that fibrinogen can also increase plasma thickness, so the group relied on thickness testing, which uses an antique lab test with glass tubes to assist determine blood density.
The group is proactively exploring alternative therapy options based upon this new finding, consisting of the use restorative plasma trade, which thins the blood and is a standard therapy for various other problems associated with hyperviscosity.
"Throughout plasma trade the plasma of COVID-19 clients is changed with contributed plasma," explains Maier. "This decreases the thickness by stabilizing the fibrinogen and various other factors adding to the stickiness and, possibly, may decrease clotting. Still, correlation doesn't imply causality, and we need to study this in large tests to understand whether thickness is simply a pen of illness or actually adding to clotting."
When it comes to the take home message, Maier says, "COVID-19 is a unique illness. There's more happening with these atypical blood clots compared to we first recognized. Hyperviscosity may be an i
